Clinical trial · Observational
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
CAR-T Cells - Real Life Study Of Care Pathway And Total Cost Of Care For Patients Under Car T-Cell Treatment Based On The PMSI French Database
NCT05349201CI-TRIAL-00059457completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This was a Retrospective cohort study based on the PMSI data source
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Lymphoblastic Leukemia (ALL) | Acute Lymphoblastic Leukemia | CURATED_BROADER | 0.80 |
| Diffuse Large B-Cell Lymphoma (DLBCL) | Diffuse Large B-Cell Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| KYMRIAH | Other | — | UNRESOLVED |
| YESCARTA | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Adult R/R DLBCL cohort: KYMRIAH
- description
- Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
- interventionNames
- Other: KYMRIAH
- label
- Adult R/R DLBCL cohort: YESCARTA
- description
- Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
- interventionNames
- Other: YESCARTA
- label
- ALL pediatric and young adult cohort: KYMRIAH
- description
- Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) ( refractory, in relapse post transplant or in second or later relapse
- interventionNames
- Other: KYMRIAH
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: * Patients treated with CAR-T cells from 2017 to 2019 and informed as such in the PMSI And * Patients diagnosed with ALL or DLBCL when administering CAR-T cells and * up to 25 years for patients with ALL Exclusion Criteria: * All patients treated outside the two types of indications presented in the inclusion criteria will be excluded
References
Publications (0)
Data not yet available
No reference posted for this study.